Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for MRM-3379 in Fragile X syndrome (FXS). The expected timing is based on the latest available company guidance and may change.
BLOOM trial. 11/4/25- Trial initiated. 12/1/25- First patient enrolled with topline data in 2027. 01/12/26:- BLOOM Ph2 FXS study described as ongoing with multiple cohorts; no updated topline data timing provided. 02/25/26:- MRM-3379 received United States Food and Drug Administration Fast Track designation for Fragile X syndrome. 05/06/26:- BLOOM Ph2 FXS study described as ongoing; design and endpoints reiterated with no new timing. 08/05/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.